<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-142864" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Infectious Complications of Blood Transfusion</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Buerger</surname>
            <given-names>Collin S.</given-names>
          </name>
          <aff>Baylor Scott and White</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Hanish</given-names>
          </name>
          <aff>Un. of Syracuse</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Collin Buerger declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hanish Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-142864.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>A safe and reliable blood supply is a crucial part of medical services. Modern blood banking technology has led to increased safety but should not be taken for granted. Infectious complications of blood transfusion, although rare in developed countries, can be life-threatening and lead to significant morbidity and mortality. Knowledge of infectious complications of blood transfusion is imperative for an interprofessional team regularly performing blood transfusions. This activity highlights the various bacterial and non-bacterial infection risks, mitigation strategies, emerging infectious risks, challenges in maintaining a safe blood supply in developing countries, cost considerations, and the challenge of estimating infectious risk when considering the infectious complications of blood transfusion.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the epidemiological considerations of infectious complications of blood transfusion.</p></list-item><list-item><p>Explain the various bacterial and non-bacterial infectious entities carrying the most infectious risk and the tactics utilized to decrease the risk associated with infectious complications of blood transfusion.</p></list-item><list-item><p>Describe emerging infectious risks complicating blood transfusions.</p></list-item><list-item><p>Summarize the challenges developed and non-developed countries face in maintaining a safe blood supply.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=142864&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=142864">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-142864.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Blood transfusion safety has progressed significantly in modern times. However, infectious complications of blood transfusions can still be encountered from time to time. Although any intravenously administered fluid can transmit infection, blood is a unique medium and is an exceptional mode for transmitting infection. Only through modern blood banking procedures have infectious complications associated with transfusions been reduced to their current rates.<xref ref-type="bibr" rid="article-142864.r1">[1]</xref>&#x000a0;</p>
        <p>As early as the 1930s, syphilis was the only recognized transfusion-transmitted infection (TTI). This list was expanded by the AABB (formerly the American Association of Blood Banks) until, by 2009, it included 77 organisms. Numerous important viral infections were identified&#x02014;first, hepatitis B virus (HBV), followed by human immunodeficiency virus (HIV). Additionally, there has always been a background transmission of bacteria and parasites causing TTIs, and prion transmission through transfusion was first recognized in the 1990s.&#x000a0;&#x000a0;</p>
        <p>Reduction in TTIs has been brought about by donor selection and exclusion and donation testing. For example, the estimated risk of transmission of hepatitis C virus (HCV), HIV, or HBV from a blood transfusion is less than &#x0003c;1:1,000,000. That said, emerging infections and their associated risks emphasize the ongoing need for constant horizon scanning, rapid worldwide information exchange, risk-reduction initiatives, methodical surveillance, and collection of epidemiological data to continue to keep TTIs at an all-time low.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref></p>
      </sec>
      <sec id="article-142864.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Transfusion-transmitted infection risks are numerous and can be characterized as bacterial and non-bacterial. This article attempts to include the most clinically relevant etiologies.&#x000a0;&#x000a0;</p>
        <p>
<bold>Bacterial Transfusion-Transmitted Infections</bold>
</p>
        <p>Bacterial infection stemming from transfusion is a significant cause of morbidity and mortality and has historically been underappreciated. The 2016 Annual UK Serious Hazards of Transfusion (SHOT) report suggested the main culprit of TTIs was bacterial transmission accounting for more than 10% of transfusion-associated deaths in the USA.<xref ref-type="bibr" rid="article-142864.r1">[1]</xref><xref ref-type="bibr" rid="article-142864.r2">[2]</xref>&#x000a0;</p>
        <p>The US Centers for Disease Control and Prevention performed a study called &#x02018;The Assessment of the Frequency of Blood Component Bacterial Contamination Associated with Transfusion Reaction Study&#x02019; (BaCon), the first study to look at specific characteristics related to bacterial contamination of blood products. The results collected between 1998 and 2000 showed that the risk for bacteremia due to transfusion is 1 in 100,000 units of platelets and 1 in 500,000 units of red blood cells (RBCs). The estimated risk for death from bacterial transfusion-transmitted causes is 1 in 500,000 units of platelets and 1 in 8 million units of RBCs.<xref ref-type="bibr" rid="article-142864.r3">[3]</xref>&#x000a0;</p>
        <p>Continually, the bacterial contamination risk is highest in platelet components, given their storage at room temperature compared to refrigerated components. It has been postulated that donor arm contamination, donor bacteremia, and equipment contamination are contributing sources. As such, donor health history questionnaires (DHQs), mini-physical exams, donor puncture site preparation, diversion of the initial portion of blood donation, and self-exclusion of unwell bacteremic donors combat these risks.</p>
        <p>That said, asymptomatic donor bacteremia, including Yersinia infection, has also been identified, especially given its ability to grow at colder storage temperatures. This risk has largely been reduced since prestorage leukoreduction may prevent/ inhibit Yersinia proliferation. Once introduced in the UK in 2011, platelet bacterial screening has greatly reduced the risk of TTIs due to Gram-negative bacteria previously responsible for most platelet contamination fatalities.<xref ref-type="bibr" rid="article-142864.r4">[4]</xref><xref ref-type="bibr" rid="article-142864.r5">[5]</xref><xref ref-type="bibr" rid="article-142864.r6">[6]</xref>&#x000a0;</p>
        <p>Despite these efforts, the risk of transfusion transmission - not necessarily septicemia - is relatively high at 1:30,000 for red cells and 1:3,000 for platelets, compared to the residual risk after the modern viral screening. Assuming bacterial contamination at the time of collection, colony-forming units (CFUs) / mL are low, and sepsis does not occur with transfusion.</p>
        <p>At the end of storage time, CFU / mL can increase dramatically and lead to sepsis, especially in immunocompromised individuals. Again, apheresis platelets (single-donor) and platelet concentrates (three to six donor pools) are stored at higher temperatures (20&#x000a0;to 24 degrees Celsius) with agitation for up to five days. Skin flora, including Staphylococcus and Streptococcus, thrive in these conditions and are more apt to cause bacterial septicemia once transfused. Serratia, Salmonella, and Bacillus are known to commonly contaminate platelet products as well.<xref ref-type="bibr" rid="article-142864.r7">[7]</xref><xref ref-type="bibr" rid="article-142864.r8">[8]</xref><xref ref-type="bibr" rid="article-142864.r9">[9]</xref>&#x000a0;</p>
        <p>Gram-negative bacteria initially appeared to be the most common source of contamination based on reports of small case series; however, the BaCon study showed that Gram-negative bacteria are more frequently associated with death and, therefore, were more often reported. Gram-positive bacteria are most likely more associated with contamination.<xref ref-type="bibr" rid="article-142864.r3">[3]</xref>&#x000a0;</p>
        <p>Attempts to prolong the platelet storage phase beyond five days have been limited due to bacteremic/ septic reactions seen at end storage and the unacceptable rates of bacterial transmission. Visual inspection of products before transfusion should occur. Contaminated red cell units are generally much darker due to bacterial oxygen usage, and platelets have loose &#x0201c;swirling&#x0201d; and lower pH when contamination is potentially present.<xref ref-type="bibr" rid="article-142864.r7">[7]</xref><xref ref-type="bibr" rid="article-142864.r10">[10]</xref>&#x000a0;Twenty-four percent of contaminated units were characterized by haziness or discoloration.<xref ref-type="bibr" rid="article-142864.r3">[3]</xref>&#x000a0;</p>
        <p>Suspect units should be quarantined and examined to evaluate for contamination. Care&#x000a0;is necessary to maintain proper storage temperature during transport.</p>
        <p>Regarding transfusion complications, bacterial septicemia remains the fourth leading cause of death in the United States. Presentation tends to be in the form of severe sepsis and usually presents as rapid onset fever and circulatory collapse.<xref ref-type="bibr" rid="article-142864.r4">[4]</xref></p>
        <p>Septic reactions should be suspected if the following occur:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Temperature greater than 102 degrees Fahrenheit (or higher than 2 degrees Fahrenheit or 3 degrees Celsius above baseline temperature)*&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chills</p>
          </list-item>
          <list-item>
            <p>Rigors*</p>
          </list-item>
          <list-item>
            <p>Tachycardia (heart rate greater than 40 beats over baseline)*</p>
          </list-item>
          <list-item>
            <p>Shock/falling systolic blood pressure (30 mm Hg below systolic)</p>
          </list-item>
          <list-item>
            <p>Backache</p>
          </list-item>
          <list-item>
            <p>Nausea/vomiting</p>
          </list-item>
          <list-item>
            <p>Unexplained bleeding from mucous membranes or the infusion site</p>
          </list-item>
          <list-item>
            <p>Renal failure may follow<xref ref-type="bibr" rid="article-142864.r7">[7]</xref><xref ref-type="bibr" rid="article-142864.r10">[10]</xref>&#x000a0;(*In 75% of cases, fever, rigors, or tachycardia were present within 4 hours of transfusion.)<xref ref-type="bibr" rid="article-142864.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>The following steps should occur if suspected:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Transfusion is immediately halted&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Respiratory support and institute mechanical ventilation as needed</p>
          </list-item>
          <list-item>
            <p>Cardiovascular support with vasopressors as indicated&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Start transfusion reaction workup (i.e., blood, post-transfusion urine, blood unit, and administration set sent to the lab.)</p>
          </list-item>
          <list-item>
            <p>Perform gram stain and culture from implicated unit and administration set as well as two site blood culture from patient to establish the diagnosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prompt broad-spectrum antibiotics initiation with narrowing from gram stain and cultures/ sensitivities<xref ref-type="bibr" rid="article-142864.r7">[7]</xref><xref ref-type="bibr" rid="article-142864.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>The differential diagnosis for transfusion pyrexia - defined as an increase in temperature greater than one degree Celsius from baseline or greater than 38 degrees Celsius with or without rigors/ chills occurring in the blood recipient of a unit of blood or blood component without other explanation &#x02013; is broad and includes the following:&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Febrile non Hemolytic transfusion reaction&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hemolytic transfusion reactions (Immediate and Delayed)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Transfusion transmitted malaria&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Transfusion-related acute lung injury (TRALI)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Transfusion-associated graft versus host disease (TAGVHD)&#x000a0;</p>
          </list-item>
        </list>
        <p>The clinician often requires a high index of suspicion to suspect the transfusion as the culprit of a fever. It should not be overlooked during the evaluation of pyrexia, especially after a reasonable interval from the transfusion has elapsed.<xref ref-type="bibr" rid="article-142864.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>Non-Bacterial Transfusion-Transmitted Infections</bold>
</p>
        <p><bold>Viruses</bold>&#x000a0;</p>
        <p>Again, syphilis was recognized as the first TTI in the 1930s. Since then, numerous infectious entities associated with blood transfusions have been identified.<xref ref-type="bibr" rid="article-142864.r12">[12]</xref>&#x000a0;Although it was not known that the agent of transmission for hepatitis was viruses, transfusion transmission of hepatitis has been recognized since the 1940s.<xref ref-type="bibr" rid="article-142864.r13">[13]</xref>&#x000a0;</p>
        <p>The first major viral infection recognized as causing transfusion-transmitted hepatitis was the hepatitis B virus (HBV). This was followed by &#x0201c;non-A&#x0201d; and &#x0201c;non-B&#x0201d; infection, which was later identified as hepatitis C virus (HCV), as well as human immunodeficiency virus (HIV).<xref ref-type="bibr" rid="article-142864.r2">[2]</xref>&#x000a0;</p>
        <p>Since the 1950s, safeguards to prevent hepatitis-causing TTIs have been in place, such as donor health questionnaires. Laboratory screening advanced, and tests developed in the 1990s could detect antibodies to, as well as antigens of, hepatitis viruses. Ultimately, nucleic acid testing (NAT) was created to detect genetic material from viruses in the donor. These tests and other mitigation strategies ultimately paved the way for the low risk of transmission of infection seen in modern times.<xref ref-type="bibr" rid="article-142864.r14">[14]</xref><xref ref-type="bibr" rid="article-142864.r15">[15]</xref></p>
        <p>
<bold>HBV&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>As above, HBV was a serious transfusion risk before the development of sensitive and specific tests many years ago, which led to a dramatic reduction in transmission via transfusion.<xref ref-type="bibr" rid="article-142864.r16">[16]</xref><xref ref-type="bibr" rid="article-142864.r17">[17]</xref><xref ref-type="bibr" rid="article-142864.r18">[18]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>NAT testing has further decreased the risk of HBV transmission from donors during the early stages of acute infection (i.e., window period); however, transmission is still possible as donor viral loads may be below the test level of detection.<xref ref-type="bibr" rid="article-142864.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>In the United Kingdom, routine blood donation screening may fail to detect one to two HBV infection donations per year.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Despite most cases of acute infection clearing spontaneously in immunocompetent adults, immunocompromised individuals will likely remain infected long-term, and infection from HBV can impact the treatment of the underlying condition.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>
<bold>HCV&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>As with HBV, careful donor selection, as well as HCV antibody screening, greatly reduced the rate of TTIs due to HCV in the early 1990s.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In the late 1990s, HCV NAT screening in the developed world further reduced the risk.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The last reported TTI due to HCV in the United Kingdom was in 1997.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref> &#x000a0;</p>
          </list-item>
          <list-item>
            <p>The risk of lab screening not detecting HCV-infected blood donation remains at one in many millions, and HCV TTI is exceedingly low.<xref ref-type="bibr" rid="article-142864.r19">[19]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>HIV&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Although initially thought to be rare, the ease of transmission of HIV via blood transfusion became more appreciated, especially with the spread of HIV in the 1980s and the gravity of acquired immunodeficiency syndrome prognosis.<xref ref-type="bibr" rid="article-142864.r14">[14]</xref><xref ref-type="bibr" rid="article-142864.r20">[20]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>By 1985 HIV antibody assays allowed for screening of blood donations; however, many TTIs due to HIV had occurred.<xref ref-type="bibr" rid="article-142864.r21">[21]</xref><xref ref-type="bibr" rid="article-142864.r22">[22]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Implementation of pre-donation screening has proven to be 98% effective in preventing HIV-positive donor units and coupled with the 95% effectiveness of antibody testing, the two combine for a 99.9% chance of reducing HIV TTIs.<xref ref-type="bibr" rid="article-142864.r20">[20]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>NAT has decreased the risk of HIV TTIs to 1:1.9 x 106.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Window period transmission is rare, but it can occur. This risk varies with the epidemiology of HIV infection in the donor pool.<xref ref-type="bibr" rid="article-142864.r23">[23]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Four cases of transfusion transmission of HIV occurred from 1999&#x000a0;to 2009; the last case in the United States was in 2008.<xref ref-type="bibr" rid="article-142864.r24">[24]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Hepatitis E Virus (HEV)&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Since the 1980s, HEV has been a significant cause of acute hepatitis; however, it has only recently been recognized as an important issue in developed countries.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Four genotypes exist:&#x000a0;</p>
          </list-item>
          <list-item>
            <p>G1 and G2 are water-borne, endemic, and cause large sporadic infections in the developing world&#x000a0;</p>
          </list-item>
          <list-item>
            <p>G3 and G4, which are primarily viruses of swine, are transmitted via foodborne zoonosis via consumption of undercooked pork products.<xref ref-type="bibr" rid="article-142864.r25">[25]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>HEV cases have been rising in the UK since 2010; G3 is the most common cause.<xref ref-type="bibr" rid="article-142864.r26">[26]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acute infection in immunocompromised individuals may lead to chronic hepatitis and cirrhosis, but most HEV infections are clinically asymptomatic.<xref ref-type="bibr" rid="article-142864.r27">[27]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The virus is cleared the majority of the time quickly in the immunocompetent.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Assuming viremic donation, the risk of HEV TTI is 40 to 50% in the recipient.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Unless transfusion recipients take dietary precautions, 13 donor exposures are approximately the same risk of infection as dietary exposure for one year.<xref ref-type="bibr" rid="article-142864.r28">[28]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Human T-Lymphotropic Virus (HTLV)&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>HTLV is transmitted through sexual partners, breastfeeding, and transfusion.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>It is a white-cell-associated virus, and although most infections are asymptomatic, a small number of individuals infected will develop clinical sequelae in the form of increased lifetime risk of adult T-cell leukemia/ lymphoma or HTLV-associated myelopathy/ tropical spastic paraparesis (4 to 5%).<xref ref-type="bibr" rid="article-142864.r29">[29]</xref><xref ref-type="bibr" rid="article-142864.r30">[30]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Areas with relatively high prevalence include Japan and the Caribbean, as well as areas of the Middle East, South America, and western and southern Africa.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>High infection rates in the Japanese population in the 1980s led to antibody screening.<xref ref-type="bibr" rid="article-142864.r31">[31]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In the United States, universal antibody screening began in 1988, followed by France in 1991 and the UK in 2002.<xref ref-type="bibr" rid="article-142864.r32">[32]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>in an attempt to reduce the risk of variant Creutzfeldt-Jakob disease (vCJD), leukodepletion of donor units in the UK in the 1990s&#x000a0;led to a risk reduction of 93% of HTLV infection.<xref ref-type="bibr" rid="article-142864.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>HTLV is not believed to exhibit the traditional window period of infectious viremia as it is a cell-associated virus. Transmission requires an infected white cell to come into contact with a white recipient cell.<xref ref-type="bibr" rid="article-142864.r34">[34]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Leukodepletion, therefore, ultimately leads to a remote risk of HTLV TTI in countries where prevalence is relatively infrequent, especially in a previously tested donor</p>
          </list-item>
          <list-item>
            <p>There is a low, 1:5.1 x 105 prevalence in the United States for first-time tested donors, and there is a 1:2.9 x 106 chance of TTI.<xref ref-type="bibr" rid="article-142864.r35">[35]</xref><xref ref-type="bibr" rid="article-142864.r2">[2]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The conversion rate is 25 to 63% for those receiving seropositive blood products.<xref ref-type="bibr" rid="article-142864.r36">[36]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>NAT is not performed for HTLV, and no similar tests are under development.<xref ref-type="bibr" rid="article-142864.r35">[35]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Cytomegalovirus (CMV)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Iatrogenic transmission via blood transfusion or tissue/ organ transplantation is possible; however, person-to-person contact through respiratory secretions is the primary mechanism of infection.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Following initial infection, which is often subclinical or results in mild flu-like symptoms, there is lifelong persistence of the virus within mononuclear white cells or hematopoietic progenitor cells within bone marrow following antibody development.<xref ref-type="bibr" rid="article-142864.r37">[37]</xref><xref ref-type="bibr" rid="article-142864.r38">[38]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Secondary infection can occur as the virus can be re-activated.<xref ref-type="bibr" rid="article-142864.r39">[39]</xref> &#x000a0;</p>
          </list-item>
          <list-item>
            <p>The vertical transmission rate during pregnancy is 40% and can affect neurodevelopment.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>50 to 60% of the UK population is estimated to be seropositive.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>1.1% of CMV-negative donors will seroconvert per year.<xref ref-type="bibr" rid="article-142864.r40">[40]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients most at risk of severe infection are solid organ/ hematopoietic stem cell transplant patients, preterm infants, congenital or acquired immunodeficiency, and those undergoing chemo-/radio-therapy; symptoms can include fever, pneumonitis, hepatitis, retinitis, colitis, and meningoencephalitis; this is most relevant in immunocompromised individuals.<xref ref-type="bibr" rid="article-142864.r41">[41]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Traditionally, transfusion of seronegative blood components to those at risk of infection was the primary mode of reducing transmission.<xref ref-type="bibr" rid="article-142864.r42">[42]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Modern leukocyte reduction techniques are now known to significantly reduce or even eliminate CMV transmission from blood products.<xref ref-type="bibr" rid="article-142864.r43">[43]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Emerging Viral Infections</bold><bold>&#x000a0;</bold>&#x000a0;</p>
        <p>This term is generally used to describe either newly identified infections or ones that have spread from a previous location to affect new or larger areas. Factors and conditions that promote emerging infections include air travel and increasing population mobility, asymptomatic carriers, vector existence in a new area, and climate warming. West Nile Virus in North America, Zika virus in Brazil, Chikungunya virus in Reunion, and dengue in areas such as southern France are all relatively recent examples. Interestingly, these instances of emerging infections have in common that they are arboviruses transmitted by mosquitos. As there is often a symptom-free period despite viremia, infected donors could unknowingly donate blood resulting in the risk, albeit small, of TTI.<xref ref-type="bibr" rid="article-142864.r44">[44]</xref>&#x000a0;</p>
        <p>Travel history, temperature measurement, and donor health questionnaires screen out roughly 99.5% of potentially infectious donors; however, other viruses are still not screened by history or tested for in the blood donor setting. Luckily, these tend to produce mild symptoms, be geographically isolated, or have yet to be identified as causing TTIs.<xref ref-type="bibr" rid="article-142864.r12">[12]</xref>&#x000a0;</p>
        <p>
<bold>West Nile Virus (WNV)&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mosquitos spread the virus with birds serving as the prime reservoir, but mammals are also an end host.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Infection in the majority of cases is either asymptomatic or results in mild symptoms, including headache, fever, and myalgias.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>There is a small, possibly 1%, risk of central nervous system involvement resulting in meningitis/ encephalitis.<xref ref-type="bibr" rid="article-142864.r45">[45]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Although previously an unaffected WNV area, the virus spread to North America, with the first cases being identified in New York City in 1999.<xref ref-type="bibr" rid="article-142864.r46">[46]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Global spread continued over the next five years across North America, north into Canada, and south to Latin America and the Caribbean; European spread also continued to previously unaffected areas.<xref ref-type="bibr" rid="article-142864.r47">[47]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Twenty-three patients were confirmed to have transfusion-transmitted WNV during the 2002 United States epidemic.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The average period of viremia for WNV infection only lasts six days; however, 80% of those infected are asymptomatic, resulting in symptom-free blood donation.<xref ref-type="bibr" rid="article-142864.r47">[47]</xref><xref ref-type="bibr" rid="article-142864.r2">[2]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The development of WNV genomic screening was rapid, and permanent NAT testing was put in place in the United States by 2002.<xref ref-type="bibr" rid="article-142864.r35">[35]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Zika&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>First evident in Africa in 1947, infection by Zika virus has been newly documented as transfusion transmissible.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The virus spread across Africa and Asia through the 1980s; at least 56 countries are known to have active Zika infections.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>More recently, in Brazil in 2015, in vivo-infected fetuses of mothers who had contracted the virus were found to exhibit microcephaly.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Viremia generally lasts 1-2 weeks during primary infection.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>By 2016 NAT testing was well underway in the United States and should decrease transfusion transmission risk to &#x0003c;1:1 x 106 as with HCV and HIV testing [Guidance for Industry: Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components (2016)].</p>
          </list-item>
        </list>
        <p><bold>Parasites</bold>&#x000a0;</p>
        <p>There is a risk of TTI due to parasites; several cases of babesiosis, malaria, trypanosomiasis, toxoplasmosis and other parasites have been reported. Careful screening of donors, such as recognizing travel history to endemic areas, is the primary means of mitigating the risk of TTI due to these organisms.<xref ref-type="bibr" rid="article-142864.r48">[48]</xref>&#x000a0;</p>
        <p>
<bold>Syphilis&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No cases due to blood transfusion have been reported since 1969.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Refrigeration of blood products is thought to kill spirochetes within 1-2 days.<xref ref-type="bibr" rid="article-142864.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Malaria contributes to significant morbidity and mortality following blood transfusion, especially in developing countries.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref> &#x000a0;</p>
          </list-item>
          <list-item>
            <p>This plasmodium species, with the Anopheles mosquito serving as its vector, spends part of its life cycle in hepatocytes and is an intracellular erythrocyte protozoan pathogen.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Leukocyte reduction does not seem to decrease the risk of transmission, and survival for 7-10 days for this protozoan is possible in blood containers.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Travel history and donor deferral are the primary means of reducing TTI risk as there are no FDA-approved screening tests for malaria; however, this can lead to the unnecessary exclusion of many donors.<xref ref-type="bibr" rid="article-142864.r12">[12]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Individuals born and raised in endemic areas, not travelers, resulting in the majority of risk as they may remain infected, semi-immune, and seemingly healthy. &#x000a0;</p>
          </list-item>
          <list-item>
            <p>An effective tool to retain donors is to perform antibody screening after the last exposure, usually four months, as a surrogate for transmission risk.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Studies are ongoing regarding pathogen reduction in blood products before transfusion.<xref ref-type="bibr" rid="article-142864.r12">[12]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Babesia&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Babesiosis is caused by babesia, intracellular erythrocyte protozoa closely related to Plasmodium, with humans being an accidental host.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>TTI has been documented in at least 162 red cell component transfusion events.<xref ref-type="bibr" rid="article-142864.r14">[14]</xref><xref ref-type="bibr" rid="article-142864.r49">[49]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Although the areas where the disease is endemic are limited, babesiosis is the most prevalent TTI in the United States.<xref ref-type="bibr" rid="article-142864.r50">[50]</xref> &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Babesia microti is spread by the ixodid tick in the United States; North Midwest states and New England are the most commonly cited areas.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Incubation and infectivity periods are prolonged at 1&#x000a0;to 6 weeks and 1&#x000a0;to 9 weeks, respectively.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The disease is usually mild with fevers; however, presentation in the immunocompromised can result in disseminated intravascular coagulation, hemolysis, or multi-organ dysfunction.<xref ref-type="bibr" rid="article-142864.r14">[14]</xref><xref ref-type="bibr" rid="article-142864.r49">[49]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>NAT and serologic studies can assess transfusion risk, but cost-effectiveness models have shown varying results.<xref ref-type="bibr" rid="article-142864.r50">[50]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Trypanosomiasis&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Trypanosomiasis cruzi, the organism responsible for Chagas disease, is endemic in South and Central America.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Risk mitigation is managed similarly to malaria with antibody screening to detect prior exposure and/or geographic donor deferral.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The use of pathogen inactivation can further reduce risk.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Leishmania&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intracellular macrophage/ monocyte protozoans cause leishmaniasis, with the sandfly as the vector.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In the United States, several cases of TTIs have been reported.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Given the pathogens reside in red blood cells, it is likely that leukocyte reduction significantly decreases transfusion transmission risk.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pathogen reduction technology and donor deferral based on travel history are the main risk mitigators.<xref ref-type="bibr" rid="article-142864.r12">[12]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Transmissible spongiform encephalopathies (TSEs)</bold>&#x000a0;</p>
        <p>Also known as prion diseases, TSEs are fatal diseases affecting the neurologic system of mammals.&#x000a0;Prions are not infectious per se; however, they are proteins that act as infectious particles, causing normal cellular isoforms to create disease-causing ones.<xref ref-type="bibr" rid="article-142864.r12">[12]</xref>&#x000a0;</p>
        <p>Recognized for approximately 100 years, sporadic Creutzfeldt-Jakob disease (sCJD) is the most common form of human prion disease. Familial types are far less common and are due to mutations in prion-related protein genes.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref>&#x000a0;TTI from sCJD is of little concern, and there have not been any documented human cases of transfusion transmission.<xref ref-type="bibr" rid="article-142864.r12">[12]</xref>&#x000a0;</p>
        <p>Variant CJD (vCJD), from which there have been TTIs documented, was recognized as a new form of human prion disease in 1996 and was a result of the foodborne transmission of the prion of bovine spongiform encephalopathy (mad cow disease). There have been reports of 230 vCJD cases in 12 countries.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref>&#x000a0;</p>
        <p>The vector of the disease is unknown, but humans and cattle serve as reservoirs. There is an intravascular phase before symptoms, and widespread replication and deposition in lymphoreticular tissues follow, at least in animal experiments. The physiochemical characteristics likely allow the prion to survive in most storage conditions. Infection is followed by incubation of 5-15 years, but incubation with transfusion is faster at 5&#x000a0;to 8 years. Leukocyte reduction, nanofiltration, and affinity-based prion removal have been explored to decrease disease transfusion risk.<xref ref-type="bibr" rid="article-142864.r12">[12]</xref> &#x000a0;</p>
        <p><bold>Risks in Developing Countries</bold>&#x000a0;</p>
        <p>In high-income countries, the availability and safety of blood transfusion are often taken for granted. However, the safe blood supply in many parts of the world is far from reliable. Many hurdles exist, including social, cultural, and medical infrastructure, donor pool and recruitment, organization of the collection, blood testing, required clinical and laboratory skills for blood use, and disease prevalence, to name a few.</p>
        <p>For example, in sub-Saharan Africa, which is characterized by many of these issues, the overall prevalence of HIV antibody is between 0.5 and 16%.; chronic hepatitis prevalence ranges between 5&#x000a0;to 25%; plasmodium species, such as malaria, is often in 16&#x000a0;to 55% of donor blood.</p>
        <p>However, substantial efforts have been made to improve coverage and test sensitivity and quality. This international push has resulted in the number of countries screening for HBV and HCV to at least 95%. The national median prevalence for HBV and HCV reactive blood donations decreased between 2004 and 2011. Also, across Africa, there has been a reduction in HCV prevalence in chronically transfused patients, suggesting improvement on these fronts. Despite these improvements, the risk of blood donation during the window period of infection remains a possibility, and donor deferral to limit TTIs is not always practical, given the limited donor pool and high disease prevalence.</p>
        <p>Maintaining a volunteer donor pool is often challenging given the complexity and expense of the collection teams, education programs, vehicles, and cold storage involved. As such, it was estimated by the World Health Organization (WHO) in 2002 that over 60% of blood in Africa originated from family, also known as replacement donors; this proportion is almost certainly higher in sub-Saharan Africa.</p>
        <p>Many patients in developing countries also present late in their disease course, and urgent transfusion needs coupled with shortages of blood result in the possibility that patients may die before blood products can be acquired and prepared. Taken together, the WHO has identified four key objectives for blood services to ensure that blood is safe for transfusion:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Establish a coordinated national blood transfusion service that can provide adequate and timely supplies of safe blood for all patients in need.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Collect blood only from voluntary nonremunerated blood donors from low-risk populations, and use stringent donor selection procedures.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Screen all blood for transfusion-transmissible infections, and have standardized procedures in place for grouping and compatibility testing.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Reduce unnecessary transfusions through the appropriate clinical use of blood, including the use of intravenous replacement fluids and other simple alternatives to transfusion, wherever possible.&#x0201d;&#x000a0;</p>
          </list-item>
        </list>
        <p>Each of these objectives has its challenges when applied to developing countries; however, work is ongoing to ensure a safe blood supply on the global level.<xref ref-type="bibr" rid="article-142864.r51">[51]</xref>&#x000a0;&#x000a0;</p>
        <p><bold>Cost</bold><bold>&#x000a0;</bold>&#x000a0;</p>
        <p>In the United States, it is the role of the Food and Drug Administration (FDA) to ensure patients who are to receive blood transfusions are protected by multiple overlapping safeguards, including donor screening, blood testing, donor deferral lists, and identification of problems and deficiencies with blood centers.</p>
        <p>All of this carries with it significant monetary costs. For example, tests on blood products include those for HBV, HCV, HIV, HTLV, and syphilis, as well as recommended testing for WNV and Chagas disease; this has brought blood donor center costs regarding infectious disease testing from $30 in 1994 for one unit of red cells to $193 for one unit of leukocyte reduced red cells (Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for Fiscal Year 2014).</p>
        <p>
<bold>Clinical Challenges</bold>
</p>
        <p>
<bold>Measuring Risk Due to Viral TTIs</bold>
</p>
        <p>Viral infections due to blood transfusion are exceedingly uncommon in developed countries, and screening questionnaires and NAT have worked to create the safest blood components transfused to date.&#x000a0;But there remain additional challenges that must be tackled. For one, it is difficult to estimate the residual risk of viral TTIs, and risk estimates can now only be estimated statistically with mathematical models.</p>
        <p>Additionally, the modeling estimates often overestimated the number of cases seen, suggesting both the success of advances in laboratory screening and the challenges in identifying TTIs from viruses in the clinical setting. There is also considerable lag time, assuming correctly identified, from transfusion to recognition of viral blood-borne pathogen infection; therefore, clinicians need to ascertain transfusion history in those contracting viral blood-borne pathogens for reporting purposes.<xref ref-type="bibr" rid="article-142864.r52">[52]</xref>&#x000a0; &#x000a0;</p>
        <p>
<bold>The Window Period and Balancing Cost with Safety</bold>
</p>
        <p>With the newest NAT screening capabilities, the &#x0201c;window period,&#x0201d; or the time from infection to seroconversion, has been greatly reduced. For example, the window for&#x000a0;HIV has decreased to 11 days and 8 to 10 days for HCV. This is a remarkable feat in modern transfusion medicine, further reducing the risk of viral TTIs.<xref ref-type="bibr" rid="article-142864.r53">[53]</xref>&#x000a0;</p>
        <p>However, as discussed above, with each new screening assay/ safety initiative, there are costs involved and the possibility of&#x000a0;diminishing returns given the very low current risks. It is a constant challenge for health services, blood banks, and governments to constantly balance the improvement&#x000a0;in safety against the price incurred.<xref ref-type="bibr" rid="article-142864.r2">[2]</xref>&#x000a0;</p>
        <p>For example, in low prevalence areas, the cost-effectiveness of NAT testing is uniformly poor. In other areas where the window period donation risk is judged high enough, such as the HIV window period in South Africa and Thailand, testing may be utilized.<xref ref-type="bibr" rid="article-142864.r54">[54]</xref><xref ref-type="bibr" rid="article-142864.r55">[55]</xref>&#x000a0;</p>
        <p>To further obfuscate the issue, these entities entrusted with transfusion safety must combat the risks constantly posed by emerging infections. Some have little or unknown clinical significance, even if associated with transfusion transmission.&#x000a0;</p>
        <p>
<bold>Special Populations</bold>
</p>
        <p>It is no surprise that populations in need of frequent blood transfusions are at increased risk for TTIs. Special attention and a high index of suspicion for TTIs should be applied to patients with blood dyscrasia, such as sickle cell anemia, thalassemia, and hemophilia, or cancer patients undergoing chemotherapy, given their possible exposure to many donor units. Initial presentation of TTI may be more severe and affect the underlying treatment of ongoing disease compared to their immunocompetent counterparts. &#x000a0;</p>
        <p>
<bold>COVID-19 Considerations</bold>
</p>
        <p>The COVID-19 pandemic has had several repercussions on maintaining a safe blood supply. These challenges have largely resulted in decreased supply attributed to additional screening procedures for donors. To combat this, deferral guidelines were eased in some regards, and elective surgeries were recommended to be postponed at times, pending the burden of the pandemic on the health care system as a whole.</p>
        <p>The parity of blood supply and donation was also improved with stringent transfusion appropriate guidelines, blood-sparing strategies (i.e., cell salvage, hemodilution, and minimally invasive surgery), and&#x000a0;pharmaceutical products.&#x000a0;Luckily, respiratory viruses are not considered TTIs, and coronaviruses have not been reported as being transfusion permissible. Regardless, donors must be healthy before donation, meet existing screening measures, and report the development of symptoms of COVID-19 post-donation, which may result in the recall of donated units to maintain blood product safety.</p>
      </sec>
      <sec id="article-142864.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>As we advance into the 21st century, blood transfusion safety continues to improve given advances in laboratory testing of donor units; however, there will almost certainly be a non-zero risk that continues to exist given the background of bacterial contamination of blood products, viral window periods, lack of resources in developing countries, and emerging infections.</p>
        <p>Clinicians should be aware of standard testing procedures of blood units before transfusion at their home institutions and the relative prevalence of disease to anticipate infectious complications of blood transfusions. Unrecognized TTIs may have significant morbidity and mortality associated with delayed diagnosis; careful considerations of the above entities should occur in the appropriate clinical context.</p>
      </sec>
      <sec id="article-142864.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>There are many steps in providing patients with safe blood products. Transfusions should be based on clinical assessment and current guidelines. Unnecessary transfusion should be avoided as limiting exposure to blood products is the primary prevention of TTIs. Implementing advanced testing, such as NAT, has significantly advanced transfusion medicine safety regarding infectious entities; however, these advancements are not universal.&#x000a0;</p>
        <p>Close communication between blood banks and clinical services is crucial in establishing safe transfusion practices. Hemovigilance also keeps track of adverse events and helps develop better policies to reduce the chance of TTIs.&#x000a0;</p>
        <p>As medicine is ever-changing, we&#x000a0;must keep ourselves updated with the latest guidelines in transfusion. Participation in conferences, CMEs, and symposiums helps transfer and improve patient care through the most up-to-date evidence regarding preventing transfusion complications. Regular interaction between blood bank staff, donation centers, and the patient is crucial.</p>
      </sec>
      <sec id="article-142864.s6" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>The transfusion chain is made up of many team members, including clinicians, phlebotomists, blood bank personnel/ laboratories, and nurses, and they play an essential role in preventing and preventing transfusion-related infections. The importance of correctly&#x000a0;obtaining, storing, and administering blood products and recipient monitoring post-transfusion cannot be understated as the integrity of the blood product supply chain depends on it.&#x000a0;Proper training and regular education of this interdisciplinary team are&#x000a0;vital in continuing to maintain and further improve the safety of blood transfusions.</p>
      </sec>
      <sec id="article-142864.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=142864&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=142864">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/142864/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=142864">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-142864.s8">
        <title>References</title>
        <ref id="article-142864.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dellinger</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Anaya</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Infectious and immunologic consequences of blood transfusion.</article-title>
            <source>Crit Care</source>
            <year>2004</year>
            <volume>8 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>S18</fpage>
            <page-range>S18-23</page-range>
            <pub-id pub-id-type="pmid">15196317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ainley</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Hewitt</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Haematology patients and the risk of transfusion transmitted infection.</article-title>
            <source>Br J Haematol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>180</volume>
            <issue>4</issue>
            <fpage>473</fpage>
            <page-range>473-483</page-range>
            <pub-id pub-id-type="pmid">29363748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuehnert</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Haley</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Elder</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Arduino</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Jarvis</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-transmitted bacterial infection in the United States, 1998 through 2000.</article-title>
            <source>Transfusion</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>12</issue>
            <fpage>1493</fpage>
            <page-range>1493-9</page-range>
            <pub-id pub-id-type="pmid">11778062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palavecino</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Yomtovian</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Bacterial contamination of platelets.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-82</page-range>
            <pub-id pub-id-type="pmid">19939734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrett</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of tobacco and alcohol consumption on the Langerhans cell population of human lingual epithelium determined using a monoclonal antibody against HLADR.</article-title>
            <source>J Oral Pathol Med</source>
            <year>1991</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>49</fpage>
            <page-range>49-52</page-range>
            <pub-id pub-id-type="pmid">2016696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McGuane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hartley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verlander</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barbara</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A novel rapid and effective donor arm disinfection method.</article-title>
            <source>Transfusion</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-8</page-range>
            <pub-id pub-id-type="pmid">19682338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagner</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>RY</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-associated bacterial sepsis.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>1994</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>290</fpage>
            <page-range>290-302</page-range>
            <pub-id pub-id-type="pmid">7923050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corash</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>509</fpage>
            <page-range>509-25</page-range>
            <pub-id pub-id-type="pmid">21939419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramirez-Arcos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DiFranco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Residual risk of bacterial contamination of platelets: six years of experience with sterility testing.</article-title>
            <source>Transfusion</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>9</issue>
            <fpage>2174</fpage>
            <page-range>2174-2181</page-range>
            <pub-id pub-id-type="pmid">28653472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodnough</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Panigrahi</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Blood Transfusion Therapy.</article-title>
            <source>Med Clin North Am</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>101</volume>
            <issue>2</issue>
            <fpage>431</fpage>
            <page-range>431-447</page-range>
            <pub-id pub-id-type="pmid">28189180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arewa</surname>
                <given-names>OP</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of transfusion pyrexia: a review of differential diagnosis and management.</article-title>
            <source>ISRN Hematol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>524040</fpage>
            <pub-id pub-id-type="pmid">23119174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hollinger</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kleinman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Metzel</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>RY</given-names>
              </name>
            </person-group>
            <article-title>Emerging infectious disease agents and their potential threat to transfusion safety.</article-title>
            <source>Transfusion</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>49 Suppl 2</volume>
            <fpage>1S</fpage>
            <page-range>1S-29S</page-range>
            <pub-id pub-id-type="pmid">19686562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tobler</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>History of posttransfusion hepatitis.</article-title>
            <source>Clin Chem</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>8 Pt 2</issue>
            <fpage>1487</fpage>
            <page-range>1487-93</page-range>
            <pub-id pub-id-type="pmid">9265899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodd</surname>
                <given-names>RY</given-names>
              </name>
            </person-group>
            <article-title>Emerging pathogens in transfusion medicine.</article-title>
            <source>Clin Lab Med</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>499</fpage>
            <page-range>499-509</page-range>
            <pub-id pub-id-type="pmid">20513567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleinman</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>The risks of transfusion-transmitted infection: direct estimation and mathematical modelling.</article-title>
            <source>Baillieres Best Pract Res Clin Haematol</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>631</fpage>
            <page-range>631-49</page-range>
            <pub-id pub-id-type="pmid">11102281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aach</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Post-transfusion hepatitis: current perspectives.</article-title>
            <source>Ann Intern Med</source>
            <year>1980</year>
            <month>Apr</month>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>539</fpage>
            <page-range>539-46</page-range>
            <pub-id pub-id-type="pmid">6987932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shorey</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The current status of non-A, non-B viral hepatitis.</article-title>
            <source>Am J Med Sci</source>
            <year>1985</year>
            <month>Jun</month>
            <volume>289</volume>
            <issue>6</issue>
            <fpage>251</fpage>
            <page-range>251-61</page-range>
            <pub-id pub-id-type="pmid">2408471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Candotti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allain</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-transmitted hepatitis B virus infection.</article-title>
            <source>J Hepatol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>798</fpage>
            <page-range>798-809</page-range>
            <pub-id pub-id-type="pmid">19615780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soldan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Barbara</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ramsay</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001.</article-title>
            <source>Vox Sang</source>
            <year>2003</year>
            <month>May</month>
            <volume>84</volume>
            <issue>4</issue>
            <fpage>274</fpage>
            <page-range>274-86</page-range>
            <pub-id pub-id-type="pmid">12757501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cumming</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Schorr</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>RY</given-names>
              </name>
            </person-group>
            <article-title>Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative.</article-title>
            <source>N Engl J Med</source>
            <year>1989</year>
            <month>Oct</month>
            <day>05</day>
            <volume>321</volume>
            <issue>14</issue>
            <fpage>941</fpage>
            <page-range>941-6</page-range>
            <pub-id pub-id-type="pmid">2779616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ammann</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wara</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Weintrub</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dritz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Acquired immunodeficiency in an infant: possible transmission by means of blood products.</article-title>
            <source>Lancet</source>
            <year>1983</year>
            <month>Apr</month>
            <day>30</day>
            <volume>1</volume>
            <issue>8331</issue>
            <fpage>956</fpage>
            <page-range>956-8</page-range>
            <pub-id pub-id-type="pmid">6132270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>McVerry</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Cheingsong-Popov</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tedder</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Seroconversion for HTLV-III since 1980 in British haemophiliacs.</article-title>
            <source>Lancet</source>
            <year>1985</year>
            <month>Feb</month>
            <day>09</day>
            <volume>1</volume>
            <issue>8424</issue>
            <fpage>336</fpage>
            <pub-id pub-id-type="pmid">2857382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crawford</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Follett</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Who may give blood?</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1987</year>
            <month>Feb</month>
            <day>28</day>
            <volume>294</volume>
            <issue>6571</issue>
            <fpage>572</fpage>
            <pub-id pub-id-type="pmid">3103781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>HIV transmission through transfusion --- Missouri and Colorado, 2008.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2010</year>
            <month>Oct</month>
            <day>22</day>
            <volume>59</volume>
            <issue>41</issue>
            <fpage>1335</fpage>
            <page-range>1335-9</page-range>
            <pub-id pub-id-type="pmid">20966896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Said</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ijaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chand</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kafatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tedder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis E virus in England and Wales: indigenous infection is associated with the consumption of processed pork products.</article-title>
            <source>Epidemiol Infect</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>142</volume>
            <issue>7</issue>
            <fpage>1467</fpage>
            <page-range>1467-75</page-range>
            <pub-id pub-id-type="pmid">24054519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ijaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Said</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Boxall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smit</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tedder</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Indigenous hepatitis E in England and wales from 2003 to 2012: evidence of an emerging novel phylotype of viruses.</article-title>
            <source>J Infect Dis</source>
            <year>2014</year>
            <month>Apr</month>
            <day>15</day>
            <volume>209</volume>
            <issue>8</issue>
            <fpage>1212</fpage>
            <page-range>1212-8</page-range>
            <pub-id pub-id-type="pmid">24273173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Selves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mansuy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ouezzani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>P&#x000e9;ron</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Guitard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cointault</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abravanel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Danjoux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Durand</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vinel</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Izopet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rostaing</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis E virus and chronic hepatitis in organ-transplant recipients.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Feb</month>
            <day>21</day>
            <volume>358</volume>
            <issue>8</issue>
            <fpage>811</fpage>
            <page-range>811-7</page-range>
            <pub-id pub-id-type="pmid">18287603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tedder</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ijaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kitchen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ushiro-Lumb</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tettmar</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Hewitt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis E risks: pigs or blood-that is the question.</article-title>
            <source>Transfusion</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>267</fpage>
            <page-range>267-272</page-range>
            <pub-id pub-id-type="pmid">28194857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rod&#x000e9;s</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Poveda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soriano</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor.</article-title>
            <source>Transplantation</source>
            <year>2003</year>
            <month>Jan</month>
            <day>15</day>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-4</page-range>
            <pub-id pub-id-type="pmid">12544880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagamine</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Horiuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanahashi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Human T lymphotropic virus type-1-associated myelopathy manifesting shortly after living-donor renal transplantation.</article-title>
            <source>Intern Med</source>
            <year>2015</year>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-8</page-range>
            <pub-id pub-id-type="pmid">25742898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inaba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okochi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takakura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tokunaga</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kiyokawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Prevention of transmission of human T-lymphotropic virus type 1 (HTLV-1) through transfusion, by donor screening with antibody to the virus. One-year experience.</article-title>
            <source>Transfusion</source>
            <year>1989</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-11</page-range>
            <pub-id pub-id-type="pmid">2643213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davison</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Dow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barbara</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hewitt</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Eglin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The introduction of anti-HTLV testing of blood donations and the risk of transfusion-transmitted HTLV, UK: 2002-2006.</article-title>
            <source>Transfus Med</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-34</page-range>
            <pub-id pub-id-type="pmid">19302452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hewitt</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Davison</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Human T-lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction.</article-title>
            <source>Transfusion</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>2168</fpage>
            <page-range>2168-75</page-range>
            <pub-id pub-id-type="pmid">23384161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demontis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sadiq</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Golz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>HTLV-1 viral RNA is detected rarely in plasma of HTLV-1 infected subjects.</article-title>
            <source>J Med Virol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>87</volume>
            <issue>12</issue>
            <fpage>2130</fpage>
            <page-range>2130-4</page-range>
            <pub-id pub-id-type="pmid">25982784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety.</article-title>
            <source>Transfus Clin Biol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-9</page-range>
            <pub-id pub-id-type="pmid">26778839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control (CDC)</collab>
            <article-title>Update: serologic testing for human T-lymphotropic virus type I--United States, 1989 and 1990.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>1992</year>
            <month>Apr</month>
            <day>17</day>
            <volume>41</volume>
            <issue>15</issue>
            <fpage>259</fpage>
            <page-range>259-62</page-range>
            <pub-id pub-id-type="pmid">1557018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pamphilon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Rider</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Barbara</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Prevention of transfusion-transmitted cytomegalovirus infection.</article-title>
            <source>Transfus Med</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-23</page-range>
            <pub-id pub-id-type="pmid">10354380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauss</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Optimal prevention of transfusion-transmitted cytomegalovirus (TTCMV) infection by modern leukocyte reduction alone: CMV sero/antibody-negative donors needed only for leukocyte products.</article-title>
            <source>Transfusion</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>8</issue>
            <fpage>1921</fpage>
            <page-range>1921-4</page-range>
            <pub-id pub-id-type="pmid">27500914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lancini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Faddy</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Flower</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cytomegalovirus disease in immunocompetent adults.</article-title>
            <source>Med J Aust</source>
            <year>2014</year>
            <month>Nov</month>
            <day>17</day>
            <volume>201</volume>
            <issue>10</issue>
            <fpage>578</fpage>
            <page-range>578-80</page-range>
            <pub-id pub-id-type="pmid">25390262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Unmack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steppat</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Juhl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>G&#x000f6;rg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hennig</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The natural course of primary cytomegalovirus infection in blood donors.</article-title>
            <source>Vox Sang</source>
            <year>2010</year>
            <month>Jul</month>
            <day>01</day>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-33</page-range>
            <pub-id pub-id-type="pmid">20074081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-transmitted CMV infection&#x000a0;-&#x000a0;current knowledge and future perspectives.</article-title>
            <source>Transfus Med</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>238</fpage>
            <page-range>238-248</page-range>
            <pub-id pub-id-type="pmid">28643867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldfinger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fernando</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Ziman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.</article-title>
            <source>Vox Sang</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>98</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">19695013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cable</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dorsey</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hapip</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Melmed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trouern-Trend</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Champion</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction.</article-title>
            <source>Transfusion</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>776</fpage>
            <page-range>776-86</page-range>
            <pub-id pub-id-type="pmid">19912585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barjas-Castro</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Angerami</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nogueira</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Rocco</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Vasami</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boin</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Stucchi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Resende</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>de Souza</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>da Fonseca</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Addas-Carvalho</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Probable transfusion-transmitted Zika virus in Brazil.</article-title>
            <source>Transfusion</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>1684</fpage>
            <page-range>1684-8</page-range>
            <pub-id pub-id-type="pmid">27329551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayes</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Sejvar</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Zaki</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lanciotti</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bode</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Virology, pathology, and clinical manifestations of West Nile virus disease.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>1174</fpage>
            <page-range>1174-9</page-range>
            <pub-id pub-id-type="pmid">16102303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nash</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mostashari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Leary</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Layton</surname>
                <given-names>M</given-names>
              </name>
              <collab>1999 West Nile Outbreak Response Working Group</collab>
            </person-group>
            <article-title>The outbreak of West Nile virus infection in the New York City area in 1999.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Jun</month>
            <day>14</day>
            <volume>344</volume>
            <issue>24</issue>
            <fpage>1807</fpage>
            <page-range>1807-14</page-range>
            <pub-id pub-id-type="pmid">11407341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayes</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Komar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nasci</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>O'Leary</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and transmission dynamics of West Nile virus disease.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>1167</fpage>
            <page-range>1167-73</page-range>
            <pub-id pub-id-type="pmid">16102302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Diseases transmitted by blood transfusion.</article-title>
            <source>Hum Pathol</source>
            <year>1983</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-7</page-range>
            <pub-id pub-id-type="pmid">6403450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiebig</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Emerging infections in transfusion medicine.</article-title>
            <source>Clin Lab Med</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>797</fpage>
            <page-range>797-823, viii</page-range>
            <pub-id pub-id-type="pmid">15325065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bish</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Moritz</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>El-Amine</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bish</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Cost-effectiveness of Babesia microti antibody and nucleic acid blood donation screening using results from prospective investigational studies.</article-title>
            <source>Transfusion</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>55</volume>
            <issue>9</issue>
            <fpage>2256</fpage>
            <page-range>2256-71</page-range>
            <pub-id pub-id-type="pmid">25995054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Problems and Approaches for Blood Transfusion in the Developing Countries.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>477</fpage>
            <page-range>477-95</page-range>
            <pub-id pub-id-type="pmid">27040966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haass</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Sapiano</surname>
                <given-names>MRP</given-names>
              </name>
              <name>
                <surname>Savinkina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuehnert</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Basavaraju</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance Module.</article-title>
            <source>Transfus Med Rev</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>84</fpage>
            <page-range>84-91</page-range>
            <pub-id pub-id-type="pmid">30930009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Busch</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kleinman</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Nemo</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Current and emerging infectious risks of blood transfusions.</article-title>
            <source>JAMA</source>
            <year>2003</year>
            <month>Feb</month>
            <day>26</day>
            <volume>289</volume>
            <issue>8</issue>
            <fpage>959</fpage>
            <page-range>959-62</page-range>
            <pub-id pub-id-type="pmid">12597733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>AuBuchon</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations.</article-title>
            <source>Transfusion</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>721</fpage>
            <page-range>721-9</page-range>
            <pub-id pub-id-type="pmid">12757522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-142864.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vermeulen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lelie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sykes</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Crookes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Swanevelder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gaggia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Le Roux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuun</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gulube</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.</article-title>
            <source>Transfusion</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>1115</fpage>
            <page-range>1115-25</page-range>
            <pub-id pub-id-type="pmid">19309474</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
